FDA GRAS No Objection Letter for FUGEIA's Brana Vita (TM) Prebiotic Wheat Bran Extract

LEUVEN, Belgium, December 9, 2010 - FUGEIA today announced that it has received the FDA No
Objection Letter with regard to the GRAS (Generally Recognized As Safe)
status of its Brana Vita (TM) wheat bran extract. This innovative product is
rich in cell wall derived arabinoxylan oligosaccharides (AXOS) ; a family of
natural soluble fibre constituents. The AXOS in Brana Vita(TM) are very
potent prebiotics, stimulating the growth of beneficial colon bacteria such
as bifidobacteria. The ingredient also exerts strong antioxidant activity
due to the presence of AXOS-bound polyphenols. FUGEIA's product thus
addresses the need of food companies keen to make great tasting foods
harbouring the goodness of wheat bran to deliver health benefits to the
consumer.

"The GRAS status of Brana Vita (TM) underscores its safety. This
is consistent with its origin from wheat bran origin a healthy food product
with a long history of safe human consumption. With this approval, the
regulatory path for commercialisation of our ingredient in the U.S.A. is
cleared. It is an important step in our overall strategy towards achieving
regulatory clearance in all major global markets, as authorities in several
countries carefully consider the GRAS status," said Willem Broekaert, the
Company's Chief Technology Officer.

Herman Van Mellaert, the Company's Chief Executive Officer
added: "This is an important milestone for our Company and for our customers
preparing product launches in the United States. Food companies want to
differentiate their products by delivering great taste and specific health
benefits to consumers. With Brana Vita (TM) we offer them a natural
ingredient from a trusted origin to achieve these goals. The results
achieved across a wide range of food categories have been very exciting.
Our partners also value the body of scientific evidence that we have created
to back up a high-impact commercial launch."

About Fugeia (www.fugeia.com)

FUGEIA develops proprietary ingredients and processes for
innovative value-added foods with health benefits. The Company was founded
early 2008 in Leuven, Belgium as a spin-off from the University of Leuven and
KaHo University College. The Company's international investor consortium
includes Tate & Lyle Ventures, Agri Investment Fund, Gemma Frisius Fund, KBC
and BNPParibasFortis.

For further information, please contact: Herman Van Mellaert, FUGEIA NV, Gaston Geenslaan 1, B-3001 Leuven, Belgium, Tel.: +32-16-751375, Fax: +32-16-751378, E-mail: info at fugeia.com